FDA Seeks Rare Vision Loss Warning for GLP-1 Drugs

The FDA's warning about rare vision loss associated with GLP-1 drugs could create negative pressure on Eli Lilly's products such as Trulicity. Despite a 24-hour decline and the RSI being above 50, the MACD's strong positive momentum and the price's position above the SMA20/50 indicate technical resistance. In the short term (1-3 days), the market may slightly feel the negative impact of the news, but technical indicators suggest this decline will remain limited. Investors should consider that the price may remain within short-term fluctuations following the news.

The FDA's request to add a rare vision loss warning to GLP-1 group drugs is a near-term negative news flow for NVO and could increase its risk premium. However, the RSI is at 60 and the price is trading above the SMA20/SMA50, indicating that selling pressure may remain limited. Since the 24-hour change is already around -3%, part of the news may already be priced in. MACD is in positive territory and above its signal line; this technical picture does not support an overly bearish expectation. Overall, I expect a slightly downward but low-confidence impact.